Comparability of serum prostate-specific antigen measurement between the Roche Diagnostics Elecsys 2010 and the Abbott Architect i2000.
BACKGROUND
Most prostate cancers are characterized by a significant rise in the production of serum prostate-specific antigen (PSA), which is used widely in screening for prostate cancer. Within New Zealand, PSA is measured on automated immunoassay analysers, including models by Abbott Laboratories (Architect i2000) and Roche Diagnostics (Elecsys 2010). These assays produce similar, but not identical, results.


OBJECTIVE
To compare the measurement of PSA between the Elecsys 2010 and the Architect i2000 assay.


METHODS
We measured PSA concentrations in each of 194 serum samples using both the Roche Elecsys 2010 and the Abbott Architect i2000 and compared the results using various statistical methods.


RESULTS
PSA concentrations measured on the Architect i2000 system were less than those on the Elecsys 2010 system, by an average of 11%.


CONCLUSIONS
Because the results from the two assays are different, reference intervals appropriate to the method of PSA measurement should be used.
Gray
Marion A
MA
Department of Public Health, Wellington School of Medicine and Health Sciences, University of Otago, Wellington, New Zealand. mgray@wnmeds.ac.nz
Cooke
Russell R
RR
Weinstein
Philip
P
Nacey
John N
JN
D006801:Humans; D007118:Immunoassay / Q000379:methods* / Q000592:standards; D008297:Male; D009520:New Zealand; D017430:Prostate-Specific Antigen / Q000032:analysis / Q000097:blood*; D011471:Prostatic Neoplasms / Q000097:blood / Q000175:diagnosis*; D011933:Reagent Kits, Diagnostic / Q000145:classification / Q000592:standards; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D013223:Statistics as Topic
D011933:Reagent Kits, Diagnostic; D017430:Prostate-Specific Antigen